Literature DB >> 23350614

Prenatal testing for Huntington's disease in the Netherlands from 1998 to 2008.

M C van Rij1, P A M de Koning Gans, C M Aalfs, M Elting, P F Ippel, J A Maat-Kievit, S Vermeer, C C Verschuuren-Bemelmans, M J van Belzen, R D M Belfroid, M Losekoot, J P M Geraedts, R A C Roos, A Tibben, C E M de Die-Smulders, E K Bijlsma.   

Abstract

This study aims to give an overview of the number of prenatal tests for Huntington's disease (HD), test results, and pregnancy outcomes in the Netherlands between 1998 and 2008 and to compare them with available data from the period 1987 to 1997. A total of 126 couples underwent prenatal diagnosis (PND) on 216 foetuses: 185 (86%) direct tests and 31 (14%) exclusion tests. In 9% of direct tests the risk for the foetus was 25%. Four at-risk parents (4%) carried intermediate alleles. Ninety-one foetuses had CAG expansions ≥36% or 50% risk haplotypes: 75 (82%) were terminated for HD, 12 (13%) were carried to term; four pregnancies were miscarried, terminated for other reasons or lost to follow-up. Unaffected pregnancies (122 foetuses) resulted in the birth of 112 children. The estimated uptake of PND was 22% of CAG expansion carriers (≥36 repeats) at reproductive age. PND was used by two new subgroups: carriers of intermediate alleles and 50% at-risk persons opting for a direct prenatal test of the foetus. A significant number of HD expansion or 50% risk pregnancies were continued. Speculations were made on causative factors contributing to these continuations. Further research on these couples' motives is needed.
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Huntington's disease; PD; continued pregnancy; exclusion test; exclusion-definitive test; grey test result; intermediate allele; non-disclosure; prenatal diagnosis; reproductive decision making; uptake

Mesh:

Year:  2013        PMID: 23350614     DOI: 10.1111/cge.12090

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  2 in total

Review 1.  A case-note review of continued pregnancies found to be at a high risk of Huntington's disease: considerations for clinical practice.

Authors:  Felicity Wadrup; Simon Holden; Rhona MacLeod; Zosia Miedzybrodzka; Andrea H Németh; Shan Owens; Sara Pasalodos; Oliver Quarrell; Angus J Clarke
Journal:  Eur J Hum Genet       Date:  2019-03-19       Impact factor: 4.246

2.  Prenatal testing in Huntington disease: after the test, choices recommence.

Authors:  Hanane Bouchghoul; Stéphane-Françoise Clément; Danièle Vauthier; Cécile Cazeneuve; Sandrine Noel; Marc Dommergues; Delphine Héron; Jacky Nizard; Marcela Gargiulo; Alexandra Durr
Journal:  Eur J Hum Genet       Date:  2016-06-15       Impact factor: 4.246

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.